This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hall, J. M. Articles by McDonnell, D. P. Search for Related Content PubMed PubMed Citation Articles by Hall, J. M. Articles by McDonnell, D. P.

The Molecular Mechanisms Underlying the Proinflammatory Actions of Thiazolidinediones in Human Macrophages

Duke University Medical Center, Department of Pharmacology and Cancer Biology, Durham, North Carolina 27710

Address all correspondence and requests for reprints to: Donald P. McDonnell, Ph.D., Duke University Medical Center, Pharmacology and Cancer Biology, Box 3813, Durham, North Carolina 27710. E-mail: donald.mcdonnell{at}duke.edu.

It is hypothesized that the antiinflammatory actions of peroxisome proliferator-activated receptors (PPARs) may explain the protective effect of these receptors in diabetes, atherosclerosis, cancer, and other inflammatory diseases. However, emerging evidence for proinflammatory activities of activated PPARs is concerning in light of new studies that associate PPAR modulators with an increased incidence of both cardiovascular events in humans and the sporadic formation of tumors in rodents. In an attempt to define the role of each PPAR subtype in inflammation, we made the unexpected observation that human PPAR is a positive regulator of inflammatory responses in both monocytes and macrophages. Notably, TNF-stimulated cells administered PPAR agonists express and secrete elevated levels of inflammatory cytokines. Most surprising, however, was the finding that thiazolidinediones (TZDs) and other known PPAR ligands display different degrees of proinflammatory activities in a PPAR- and PPAR-independent manner via their ability to augment PPAR signaling. A series of mechanistic studies revealed that TZDs, at clinically relevant concentrations, bind and activate the transcriptional activity of PPAR. Collectively, these studies suggest that the observed proinflammatory and potentially deleterious effects of PPAR ligands may be mediated through an off-target effect on PPAR. These studies highlight the need for PPAR modulators with increased receptor subtype specificity. Furthermore, they suggest that differences in systemic exposure and consequently in the activation of PPAR and PPAR may explain why TZDs can exhibit both inflammatory and antiinflammatory activities in humans.

NURSA Molecule Pages Link:

Nuclear Receptors:   PPARα  |  PPARδ  |  PPARγ

Ligands:   Rosiglitazone

This article has been cited by other articles:

				S. P.B. Ramirez, J. M. Albert, M. J. Blayney, F. Tentori, D. A. Goodkin, R. A. Wolfe, E. W. Young, G. R. Bailie, R. L. Pisoni, and F. K. Port Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1094 - 1101. [Abstract] [Full Text] [PDF]

				Y. Li, A. Kovach, K. Suino-Powell, D. Martynowski, and H. E. Xu Structural and Biochemical Basis for the Binding Selectivity of Peroxisome Proliferator-activated Receptor {gamma} to PGC-1{alpha} J. Biol. Chem., July 4, 2008; 283(27): 19132 - 19139. [Abstract] [Full Text] [PDF]

				B. G. Shearer, D. J. Steger, J. M. Way, T. B. Stanley, D. C. Lobe, D. A. Grillot, M. A. Iannone, M. A. Lazar, T. M. Willson, and A. N. Billin Identification and Characterization of a Selective Peroxisome Proliferator-Activated Receptor {beta}/{delta} (NR1C2) Antagonist Mol. Endocrinol., February 1, 2008; 22(2): 523 - 529. [Abstract] [Full Text] [PDF]

				N. B. Mettu, T. B. Stanley, M. A. Dwyer, M. S. Jansen, J. E. Allen, J. M. Hall, and D. P. McDonnell The Nuclear Receptor-Coactivator Interaction Surface as a Target for Peptide Antagonists of the Peroxisome Proliferator-Activated Receptors Mol. Endocrinol., October 1, 2007; 21(10): 2361 - 2377. [Abstract] [Full Text] [PDF]